NIKKEI 225
38,525.34 -707.46 (-1.80%) HANG SENG
16,321.73 -278.73 (-1.68%) CRUDE OIL
85.95 +0.54 (+0.63%) GOLD FUTURES
2,403.90 +20.90 (+0.88%) DOW
37,735.11 -248.13 (-0.65%) Bitcoin GBP
50,410.20 -2,012.82 (-3.84%)
Pharvaris N.V. (9EN.F)
| Previous close | 20.00 |
| Open | 20.40 |
| Bid | 18.50 x N/A |
| Ask | 19.90 x N/A |
| Day's range | 18.20 - 20.40 |
| 52-week range | 7.25 - 29.60 |
| Volume | |
| Avg. volume | 13 |
| Market cap | 1.026B |
| Beta (5Y monthly) | -3.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksStrengthened executive committee with hiring of David Nassif, J.D., Chief Financial Officer, and Stefan Abele, Ph.D., as Chief Technical Operations OfficerUK Innovation Passport awarded to deucrictibant for both the on-demand and prophylactic treatment of HAE atta
- Globe Newswire
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and o
- GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX. Presentation details: Title: Early-Onset Response to the Oral Bra
